539 results about "Premalignant Neoplasm" patented technology

A method and apparatus for classifying possibly malignant lesions from sets of DCE-MRI images includes receiving a set of MRI slice images obtained at respectively different times, where each slice image includes voxels representative of at least one region of interest (ROI). The images are processed to determine the boundaries of the ROIs and the voxels within the identified boundaries in corresponding regions of the images from each time period are processed to extract kinetic texture features. The kinetic texture features are then used in a classification process which classifies the ROIs as malignant or benign. The malignant lesions are further classified to separate TN lesions from non-TN lesions.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The present invention provides compounds of the following structure, wherein R1, R2, R4, R4′, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and / or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and / or treating, and for preventing and / or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.

The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.

The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.

The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and / or treatment of neoplastic disorders and diseases.

The present invention provides a method for detecting and grading benign and malignant tumors using at least one sensor of conductive nanoparticles capped with an organic coating in conjunction with a learning and pattern recognition algorithm. The method utilizes a plurality of response induced parameters to obtain improved sensitivity and selectivity for diagnosis, prognosis, monitoring and staging various types of cancers, or for identifying or grading benign or malignant tumors.

A method and apparatus for classifying possibly malignant lesions from sets of DCE-MRI images includes receiving a set of MRI slice images obtained at respectively different times, where each slice image includes voxels representative of at least one region of interest (ROI). The images are processed to determine the boundaries of the ROIs and the voxels within the identified boundaries in corresponding regions of the images from each time period are processed to extract kinetic texture features. The kinetic texture features are then used in a classification process which classifies the ROIs as malignant or benign. The malignant lesions are further classified to separate TN lesions from non-TN lesions.

To detect a malignant tumor more accurately by detecting a feature of a cancerous tumor pulsation more appropriately, a tissue malignant tumor detection method according to the present invention includes: segmenting, into blocks, a region scanned with ultrasound (S100); estimating, based on a scan signal, a tissue pulsation that is a temporal variation in tissue displacement derived from pulsations of a tissue (S101); extracting, for each of the blocks, pulsation-related features that are parameters related to the tissue pulsation (S103); calculating distribution characteristics of the pulsation-related features for each of the blocks (S104); and classifying, based on the distribution characteristics, whether or not each of the blocks is a malignant block that is a block including the malignant tumor (S105).

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

The invention discloses particulates with double functions of internal radiotherapy and thermal therapy, and a preparation method thereof. The particulates are mainly compounded and formed by glass containing radioactive species yttrium-90 or / and phosphorus-32, and solid ferrite with magnetocaloric effect. When the particulates intervene in vivo, the radioactive species yttrium-90 or / and the phosphorus-32 contained in the glass can release Beta rays in vivo to kill cancer cells intervening in surrounding tissues without damaging the distant healthy tissues; the solid ferrite has good hysteresis exothermicity and can transform exosomatic magnetic energy into heat energy so as to release heat under the action of an external alternating magnetic field, so that the temperature around the tumor area can raise to 43 to 47 DEG C within a short time, and tumour cells intervening in the surrounding tissues are burnt and killed without influencing normal cells with better heat tolerance, thereby realizing the purpose of treating tumor by combining the internal radiotherapy and the thermotherapy, and having double lethality to cancer cells. The method for combining the radiation treatment and the heat treatment is an indispensable supplementary therapy means to treat the malignant tumor with chemical drug resistance. In addition, the particulates have good chemical stability and biocompatibility, and have great application prospect in the aspect of treating the malignant tumor.

The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L ("activator-antisense complex") which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The invention discloses a beta-carboline ruthenium compound. The molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (Nh) XClY] (A^A)z, wherein N^N is selected from bpy or phen; A^A is selected from PF6 or SO3CF3; X is equal to 1 or 2, Y is equal to 2-X, and Z is equal to 1 or 2; or the molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (1-Py-betaC)] (PF^)2, wherein N^N is selected from bpy, phen or DIP. On a molecular mechanism, the invention proves that the beta-carboline ruthenium compound can be used for treating cancers and has a better effectthan the effects of that of the traditional metal compound cisplatin with wide application and ruthenium compounds NAMI-A in clinical tests; . Thethe beta-carboline ruthenium compound for treating the cancers as an autophagic cell inducer fills the blank of the prior art and develops a new line for developing a new generation of high-efficiency medicaments for treating malignant tumors.

The invention discloses a gold nanorods based drug carrier. The carrier is characterized in that: gold nanorods is wrapped with a polyanion film layer, a polycation film layer and an hTERT gene antisense oligonucleotide layer from inside to outside. The gold nanorods based drug carrier is prepared by the layer-by-layer self-assembly principle by utilizing the electrostatic force among radicals, and can be used for preparing inhibitors for malignant tumor cell telomerase. The invention causes hTERT gene antisense oligonucleotide to be loaded on the gold nanorods for the first time to solve the problem of low transfection rate occurred in naked antisense oligonucleotide. The prepared gold nanorods based drug carrier does not only has the advantages of high transfection rate, strong targeting property, obvious effect of inhibiting the activity of the malignant tumor cell telomerase, and the like, but also has the advantages of safety and innocuity, which opens up a new way for the application of the gold nanorods in the biomedicine field; in addition, the invention has the advantages of simple operation for the preparation technology and low cost, and is suitable for scale production.

Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and / or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.

A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.

A method of detecting and diagnosing cancers characterized by the presence of at least one nodule / neoplasm from an imaging scan is presented. To detect nodules in an imaging scan, a 3D CNN using a single feed forward pass of a single network is used. After detection, risk stratification is performed using a supervised or an unsupervised deep learning method to assist in characterizing the detected nodule / neoplasm as benign or malignant. The supervised learning method relies on a 3D CNN used with transfer learning and a graph regularized sparse MTL to determine malignancy. The unsupervised learning method uses clustering to generate labels after which label proportions are used with a novel algorithm to classify malignancy. The method assists radiologists in improving detection rates of lung nodules to facilitate early detection and minimizing errors in diagnosis.

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A,wherein R is H, halo, or C1-C6 alkyl; R′ is C1-C6 alkyl; ora pharmaceutically acceptable salt thereof; andoptionally a pharmaceutically acceptable excipient; andone or more additional therapeutic agents optionally selected from the group consisting of bendamustine, rituximab, and ofatumumab.

The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and / or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.

The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. The high selectivity of the new prodrugs is probably attributed to the fact that, in the new prodrugs, a secondary halide is present in contrast to the prodrugs of a similar type previously produced by us. The direct alkylation of the DNA or RNA by the prodrugs and thus the toxicity of the prodrugs is thereby reduced. After splitting off of the glycosidic and / or acetal group on the phenolic hydroxy groups of the prodrugs, a spirocyclopropacyclohexadiene is formed which, being a highly toxic group, effects an alkylation of the DNA or RNA.

The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.

The invention provides a medicinal composition for treating digestive system dysfunction. The medicinal composition is characterized by comprising the following components in parts by weight: 10-25 parts of ginseng, 10-25 parts of bighead atractylodes rhizome, and 12-25 parts of poria. The medicinal composition is particularly suitable for treating gastrointestinal dysfunction after radiotherapy or chemotherapy, is good in curative effect, and does not have toxic or side effect; the patients have good tolerance and can easily accept the medicinal composition; the treatment cost is low. The medicinal composition can be used for treating gastrointestinal dysfunction after radiotherapy or chemotherapy independently, and also can be used for treating malignant tumor diseases by combining radiotherapy or chemotherapy.

The invention provides an application of mitoxantrone and salt thereof as a lymph tracer (such as hydrochloric acid mitoxantrone, oxalic acid mitoxantrone, sulfuric acid mitoxantrone, phosphoric acid mitoxantrone, acetic acid mitoxantrone, citric acid mitoxantrone and the like). The mitoxantrone and salt thereof can be used for preparing injection, powder injection, emulsion, liposome, nanoparticle, microballoon and the like. The mitoxantrone and salt thereof not only can be used for killing malignant tumor cells, but also the blue dye feature can be used as the lymph tracer applied to lymphadenectomy in cancer operative treatment, which is suitable for treating stomach cancer, breast cancer, intestinal cancer, cervical carcinoma, testis cancer and the like.

Three kinds of tissues including cancer tissue, precancerosis and corresponding normal tissue are sliced up, dyed, marked, and positioned. Receptor holes are prepared by leading designed lattice array mould paper to paste on surface of wax block of receptor. Wax block with tissue core bar is prepared by using perforating needle and puncture needle for tissue. Common cancer such as lung cancer, nasopharyngeal carcinoma, oesophagus cancer etc. and having integrated clinical data and pathology features are selected. Through in situ hybridization, testing mRNA of relevant gene and expression of protein on tissue chip, consistent result between the invented product and traditional test is validated. In the product, cellular morphology is clear and even, and there is no fallen off tissue point. The invention is applicable to filter cancers, early diagnosis and forecasting prognosis.

The invention disclose a pulchritude of neoplasm sera, which made up of peptide metarginase; among of which tumor is that one of breast carcinoma, liver cancer, renal carcinoma, oophoroma, carcinoma of prostate and bladder carcinoma. The invention also disclose the application of pulchritude of neoplasm sera in the clinical diagnosis reagent of preparing detect tumor. Using the tumor clinical diagnosis reagent or kit which is provided by this invention and prepared pulchritude of neoplasm sera, it can detect a guideline and realize preparatory ensure if the tester suffer from malignancy, accomplish the work of health screening with low cost in the short detect time, and provide the reliable basis for the clinical diagnosis.

The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and / or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefore Additional uses include stimulation of food intake.